{
  "hash": "a62ebd9da78dbe07",
  "original_length": 46287,
  "summary_length": 2609,
  "summary": "The Securities and Exchange Commission today announced charges against ReWalk Robotics, Ltd., formerly known as Argo Medical Technologies, Inc., a medical device company, for making materially false and misleading statements in its registration statement.  According to the SEC's complaint, filed in federal court in Boston on September 19, 2014, ReWalk and its officers and directors failed to disclose that in June 2014 the U.S. Food and Drug Administration (FDA) issued a warning to ReWalk to conduct a post-market surveillance study.  The complaint alleges that in November 2014, the FDA issued a safety and effectiveness alert for ReWalk's failure to comply with the FDA's requirements.  As alleged in the complaint, this warning letter, which was issued on or before September 2014, was false, misleading, and could not be relied upon.  In addition, the SEC alleges that ReWalk did not adequately disclose that it had developed a \"breakthrough product\" that could deliver a natural gait and functional walking speed, which has not been shown in studies for any competing exoskeleton.  Without admitting or denying the allegations in the SEC&rsquo;s complaint, the defendants consented to the entry of a final judgment that permanently enjoins them from violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) and Rule 10b-5 thereunder, and orders them to pay disgorgement of ill-gotten gains plus interest, penalties, and injunctive relief.  Additionally, the settlement is subject to court approval.  For further information, see Litigation Release No. 17-cv-5 (January 10, 2020).  The SEC&rdquo:  The Complaint alleges that the defendants violated Sections 303 and 503 of the Investment Advisers Act of 1940, and that defendants violated Section 5 of the Exchange Act for failing to adequately disclose the risks and benefits of ReWalk.  Specifically, the Complaint charges ReWalk with violating Sections 5(a), 5(c), and 20(a).  In a parallel action, the United States Attorney's Office for the Southern District of New York today announced criminal charges against the defendants.  Among other things, the complaint charges the defendants with violating Section 15(b)(5) of\u00c2\u00a0the Securities Exchange Act of 1934 and Rule 15a-1 thereunder.  Separately, the Commission has issued an order appointing a receiver to oversee the receivership of the ReWalk device, which is intended to prevent future violations of the federal securities laws. The receiver has agreed to the appointment of a receiver and to the payment of a penalty equal to the amount of disgorg"
}